Velicept Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2015-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.velicept.com
Clinical Trials
3
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)
Phase 2
Completed
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Velicept Therapeutics, Inc.
- Target Recruit Count
- 1413
- Registration Number
- NCT03594058
- Locations
- 🇺🇸
Velicept Investigative Site - Birmingham, Birmingham, Alabama, United States
🇺🇸Velicept Investigative Site - Guntersville, Guntersville, Alabama, United States
🇺🇸Velicept Investigative Site - Saraland, Saraland, Alabama, United States
Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women
Phase 2
Completed
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2018-03-23
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Velicept Therapeutics, Inc.
- Target Recruit Count
- 438
- Registration Number
- NCT03475706
- Locations
- 🇺🇸
Velicept Investigative Site - Birmingham, Birmingham, Alabama, United States
🇺🇸Velicept Investigative Site - Gulf Shores, Gulf Shores, Alabama, United States
🇺🇸Velicept Investigative Site - Mobile, Mobile, Alabama, United States
Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects, Overactive Bladder
- Interventions
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Velicept Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02938507
News
No news found